Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA). However, three-year mortality remains over...
Main Authors: | J. Silva-Cardoso, D. Brás, F. Canário-Almeida, A. Andrade, L. Oliveira, F. Pádua, C. Fonseca, N. Bragança, S. Carvalho, R. Soares, J. Ferreira Santos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | Revista Portuguesa de Cardiologia |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0870255118300635 |
Similar Items
-
Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
by: J. Silva-Cardoso, et al.
Published: (2019-03-01) -
On the nature and deginition of heart failure : Insights form inflammation, neurohormones and congenital heart disease
by: Bolger, Aidan Patrick
Published: (2011) -
The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure
by: Jorge Polónia, et al.
Published: (2019-12-01) -
Neurohormonal and inflammatory markers in valvular heart disease
by: Gerber, Ivor Leslie
Published: (2014) -
Cardiac function regulation by new neurohormones and myocardial stretch: potential pathophysiologic implications in heart failure.
by: Ana Luísa Pereira Pires
Published: (2019)